Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)

Thomas S. Scanlan

Overview

The purpose of this study is to assess the safety, tolerance, pharmacokinetics, and pharmacodynamics of sobetirome, a selective thyroid hormone analog, in adult male X-ALD patients.

Subjects will have a screening visit within 6 weeks prior to the Baseline visit. At Baseline visit blood will be drawn and to establish baseline values for plasma and red blood cell (RBC) very long chain fatty acids (VLCFA; C22, C24, and C26). Subjects will receive an oral dose of 50 mcg sobetirome once daily for 14 days beginning on Day 1. Subjects will be kept in the clinic on Day 1 for 16 hours following their initial dose of sobetirome for repeat blood sampling for pharmacokinetic analysis. Subjects will return to the clinic on days 7, 15, 21 and 28 for blood collection for VLCFA measurements. On day 15, after safety assessment, subjects will receive an increased dose of 100 mcg and this dose will be continued once daily through Day 28. Subjects will continue to return to the clinic weekly for blood and urine collection and safety assessments. Subjects will return to the clinic on day 42 for an End of Study visit that will involve a final measurement of VLCFA and blood and urine safety labs to check for reversibility. Safety labs will include serum chemistry, free fatty acid profile, hematology, urinalysis, and thyroid function. Subjects will be monitored with ECGs, vital signs, physical exams and assessment of adverse events.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

X-Linked Adrenoleukodystrophy Adrenomyeloneuropathy

Interventions

SobetiromeDRUG

50 mcg or 100 mcg once-daily oral

Eligibility

Sex: MALEMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * males 18-65 years old * X-ALD diagnosis by either elevated VLCFAs or DNA testing * must sign informed consent and agree to complete required clinic visits. Exclusion Criteria: * female gender * abnormal laboratory test results (except VLCFA) at screening visit * history of coronary artery disease * use of triiodothyronine therapy * abnormal thyroid function test at screening visit * untreated adrenal insufficiency * currently taking Lorenzo's Oil or other VLCFA lowering agent * participation in investigational drug study within 30 days

Locations (1)

Oregon Health & Science University

Portland, Oregon, United States

Outcomes

Primary Outcomes

Change from Baseline in very long chain fatty acid (VLCFA) levels

Very long chain fatty acid (VLCFA) levels in plasma and erythrocytes will be measured after 14 days of 50 mcg sobetirome, and again after 14 days of 100 mcg sobetirome dosing.

Time frame: Day 14 and Day 28 of sobetirome dosing

Secondary Outcomes

Evidence of changes in thyroid function from baseline confirmed by measured changes in TSH and/or free T4

Thyroid function will be assessed my measurement of TSH and free T4 following 14 days of 50 mcg sobetirome, and again following 14 days of 100 mcg sobetirome dosing.

Time frame: Day 14 and 28 of sobetirome dosing

Number of participants with adverse events from baseline

Adverse events will be assessed by physical examination and ECG

Time frame: Every 7 days to outcome visit day and again at end of study visit day

Peak Plasma Concentration (Cmax) of Sobetirome

A pharmacokinetic analysis to assess sobetirome exposure in X-ALD subjects.

Time frame: Day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.